SCHEMBL18925400

SCHEMBL18925400

CNC1COCCC1Nc1nc(Nc2cccc(Cl)c2)c(C(N)=O)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 12/20 0.49
▸ KCNH2 Q12809 4/20 0.49
▸ AURKB Q96GD4 4/20 0.49
▸ MAPK3 P27361 3/20 0.49
▸ MAPK1 P28482 3/20 0.49
▸ JAK2 O60674 2/20 0.49
▸ TYRO3 Q06418 2/20 0.49
▸ ROCK2 O75116 1/20 0.49
▸ MAP4K4 O95819 1/20 0.49
▸ HCK P08631 1/20 0.49
▸ ROS1 P08922 1/20 0.49
▸ PIM1 P11309 1/20 0.49
▸ PRKACA P17612 1/20 0.49
▸ MARK3 P27448 1/20 0.49
▸ LTK P29376 1/20 0.49
▸ FLT3 P36888 1/20 0.49
▸ CSNK1A1 P48729 1/20 0.49
▸ CLK2 P49760 1/20 0.49
▸ MAPK10 P53779 1/20 0.49
▸ MAP2K1 Q02750 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18926209 0.90 SYK (0.61) SYKKCNH2AURKBMAPK3MAPK1
SCHEMBL2712734 0.90 SYK (0.59) SYKKCNH2AURKBMAPK3MAPK1
SCHEMBL18925878 0.86 SYK (0.63) SYKKCNH2AURKBMAPK3MAPK1
SCHEMBL18925873 0.85 SYK (0.58) SYKKCNH2AURKBMAPK3MAPK1
SCHEMBL18926167 0.83 SYK (0.54) SYKKCNH2AURKBMAPK3MAPK1
SCHEMBL18925321 0.83 SYK (0.51) SYKKCNH2AURKBMAPK3MAPK1
SCHEMBL18926182 0.82 JAK1 (0.50) SYKKCNH2AURKBMAPK3MAPK1
SCHEMBL18925590 0.82 SYK (0.46) SYKKCNH2AURKBMAPK3MAPK1
SCHEMBL14910111 0.81 JAK2 (0.73) SYKKCNH2AURKBMAPK3MAPK1
SCHEMBL14929773 0.81 JAK2 (0.73) SYKKCNH2AURKBMAPK3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3176154-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS Portola Pharmaceuticals, Inc. (US) 2017-06-07 — — EP disclosed
US-20150272956-A1 SUBSTITUTED XANTHINE DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES, INC. 2015-10-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150272956-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 SYK 2450/4885KCNH2 2571/4885AURKB 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback